Exodus Movement acquires Uruguayan payment company Grateful to strengthen stablecoin payment business
ChainCatcher news, cryptocurrency platform Exodus Movement, Inc. (NYSE American: EXOD) announced today the acquisition of Uruguayan payment coordinator Grateful. This acquisition aims to enhance Exodus's merchant service capabilities in Latin America, particularly stablecoin-based payment solutions.
Grateful specializes in providing digital payment services for small businesses and freelancers, with platform features including low fees, instant fund access, and balance yield functionality. The company offers a complete suite of merchant tools, including a merchant dashboard, wallet-to-wallet payments, and QR code-based point-of-sale features. Exodus plans to seamlessly integrate Grateful's technology into its existing multi-chain wallet, supporting major blockchains such as Polygon, Optimism, Base, Arbitrum, and Solana. Exodus will hold an earnings call today at 8:30 AM Eastern Time to discuss the acquisition in detail.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
